JP Morgan Chase’s Skye Bioscience SKYE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44 Hold
8
﹤0.01% 7598
2026
Q1
$39 Hold
8
﹤0.01% 7374
2025
Q4
$49 Buy
+8
New +$93 ﹤0.01% 7260
2025
Q2
Sell
-1,238
Closed -$15.7K 7754
2025
Q1
$15.7K Buy
1,238
+82
+7% +$1.79K ﹤0.01% 6212
2024
Q4
$26.2K Sell
1,156
-264
-19% -$8.82K ﹤0.01% 6190
2024
Q3
$44.4K Sell
1,420
-451
-24% -$20.2K ﹤0.01% 6032
2024
Q2
$120K Buy
+1,871
New +$178K ﹤0.01% 5429

Other funds holding SKYE

JP Morgan Chase's SKYE Position: Q2 2026 in Review

JP Morgan Chase held its Skye Bioscience (SKYE) position steady in Q2 2026 at 8 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #7598.

JP Morgan Chase first reported a position in SKYE in Q2 2024 and has held it in 7 quarters since. The position peaked at $120K in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • JP Morgan Chase held 8 shares of Skye Bioscience worth $44 as of Q2 2026.
  • JP Morgan Chase left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7598 holding.
  • JP Morgan Chase first reported a position in Skye Bioscience in Q2 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Skye Bioscience position peaked at $120K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.